Literature DB >> 23381232

Encouraging efficacy of modern conformal fractionated radiotherapy in patients with uncured Cushing's disease.

Sweta Budyal1, Anurag R Lila, Rakesh Jalali, Tejpal Gupta, Rajeev Kasliwal, Varsha S Jagtap, Tushar Bandgar, Padmavathy Menon, Nalini S Shah.   

Abstract

The objective of this study was to assess the efficacy of modern conformal fractionated radiotherapy (RT) in patients with uncured Cushing's disease (CD) after failed transsphenoidal surgery (TSS). In this retrospective analysis, we reviewed records of patients with CD who received modern conformal fractionated RT between 2001 and 2010. Records were evaluated for frequency and interval of remission post RT. The change in the tumour size, endocrine insufficiencies and complications developing post RT were noted. Remission was defined as 2 mg Low dose dexamethasone suppressed cortisol of <50 nmol/l. During the study period of 10 years, a total of 24 patients (mean age: 27.9, range: 21-48 years) underwent pituitary RT for CD. Out of these, long term follow up was available for 22 patients and 20 patients (15F/5M, 12 microadenomas/8 macroadenomas) were included for final analysis. All the patients received modern conformal fractionated external beam RT (45 Gy in 25 fractions) with the median follow up of 37.5 months (range 12-144). Fifteen patients (10 microadenomas/5 macroadenomas) underwent remission after a median follow up period of 20 months. None of the patients had recurrence. Post RT, new onset endocrine deficiencies were seen in 8 (40 %) patients. Modern conformal fractionated external beam radiotherapy is an effective modality for treatment of adult patients with CD after failed TSS.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 23381232     DOI: 10.1007/s11102-013-0466-4

Source DB:  PubMed          Journal:  Pituitary        ISSN: 1386-341X            Impact factor:   4.107


  32 in total

1.  Heavy-charged-particle radiosurgery of the pituitary gland: clinical results of 840 patients.

Authors:  R P Levy; J I Fabrikant; K A Frankel; M H Phillips; J T Lyman; J H Lawrence; C A Tobias
Journal:  Stereotact Funct Neurosurg       Date:  1991       Impact factor: 1.875

2.  Outcome of using the histological pseudocapsule as a surgical capsule in Cushing disease.

Authors:  Jay Jagannathan; Rene Smith; Hetty L DeVroom; Alexander O Vortmeyer; Constantine A Stratakis; Lynnette K Nieman; Edward H Oldfield
Journal:  J Neurosurg       Date:  2009-09       Impact factor: 5.115

3.  Early repeat surgery for persistent Cushing's disease.

Authors:  Z Ram; L K Nieman; G B Cutler; G P Chrousos; J L Doppman; E H Oldfield
Journal:  J Neurosurg       Date:  1994-01       Impact factor: 5.115

4.  Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline.

Authors:  Mark E Molitch; David R Clemmons; Saul Malozowski; George R Merriam; Mary Lee Vance
Journal:  J Clin Endocrinol Metab       Date:  2011-06       Impact factor: 5.958

5.  Adrenocorticotropic hormone-producing pituitary tumors: 12- to 22-year follow-up after treatment with stereotactic radiosurgery.

Authors:  C Höybye; E Grenbäck; T Rähn; M Degerblad; M Thorén; A L Hulting
Journal:  Neurosurgery       Date:  2001-08       Impact factor: 4.654

6.  The long-term outcome of pituitary irradiation after unsuccessful transsphenoidal surgery in Cushing's disease.

Authors:  J Estrada; M Boronat; M Mielgo; R Magallón; I Millan; S Díez; T Lucas; B Barceló
Journal:  N Engl J Med       Date:  1997-01-16       Impact factor: 91.245

7.  Risk of second brain tumor after conservative surgery and radiotherapy for pituitary adenoma: update after an additional 10 years.

Authors:  G Minniti; D Traish; S Ashley; A Gonsalves; M Brada
Journal:  J Clin Endocrinol Metab       Date:  2004-11-23       Impact factor: 5.958

8.  Transsphenoidal microsurgery for Cushing's disease: initial outcome and long-term results.

Authors:  Gary D Hammer; J Blake Tyrrell; Kathleen R Lamborn; Carol B Applebury; Elizabeth T Hannegan; Scott Bell; Riva Rahl; Amy Lu; Charles B Wilson
Journal:  J Clin Endocrinol Metab       Date:  2004-12       Impact factor: 5.958

9.  Radiotherapy for pituitary adenomas: long-term efficacy and toxicity.

Authors:  Sara C Erridge; David S Conkey; Diane Stockton; Mark W J Strachan; Patrick F X Statham; Ian R Whittle; Robin Grant; Gillian R Kerr; Anna Gregor
Journal:  Radiother Oncol       Date:  2009-11-10       Impact factor: 6.280

10.  Transsphenoidal microsurgical treatment of Cushing disease: postoperative assessment of surgical efficacy by application of an overnight low-dose dexamethasone suppression test.

Authors:  Joseph C T Chen; Aitun P Amar; SooHo Choi; Peter Singer; Wnluam T Couldwell; Martin H Weiss
Journal:  J Neurosurg       Date:  2003-05       Impact factor: 5.115

View more
  4 in total

Review 1.  The Treatment of Cushing's Disease.

Authors:  Rosario Pivonello; Monica De Leo; Alessia Cozzolino; Annamaria Colao
Journal:  Endocr Rev       Date:  2015-06-11       Impact factor: 19.871

Review 2.  Update on radiation therapy in patients with Cushing's disease.

Authors:  Nicholas A Tritos; Beverly M K Biller
Journal:  Pituitary       Date:  2015-04       Impact factor: 4.107

Review 3.  STEREOTACTIC RADIATION THERAPY IN PITUITARY ADENOMAS, IS IT BETTER THAN CONVENTIONAL RADIATION THERAPY?

Authors:  M L Gheorghiu; M Fleseriu
Journal:  Acta Endocrinol (Buchar)       Date:  2017 Oct-Dec       Impact factor: 0.877

Review 4.  Recurrence after pituitary surgery in adult Cushing's disease: a systematic review on diagnosis and treatment.

Authors:  Leah T Braun; German Rubinstein; Stephanie Zopp; Frederick Vogel; Christine Schmid-Tannwald; Montserrat Pazos Escudero; Jürgen Honegger; Roland Ladurner; Martin Reincke
Journal:  Endocrine       Date:  2020-08-02       Impact factor: 3.633

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.